Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484832 | 0.86 | IMPDH2 (0.75) | IMPDH2NPC1RAB9ATP53SMN1; SMN2 | |
| SCHEMBL6494498 | 0.86 | IMPDH2 (0.74) | IMPDH2AAK1 | |
| SCHEMBL15742820 | 0.85 | IMPDH2 (0.73) | IMPDH2AAK1 | |
| SCHEMBL1475788 | 0.83 | IMPDH2 (1.00) | IMPDH2AAK1 | |
| SCHEMBL1474411 | 0.82 | IMPDH2 (1.00) | IMPDH2AAK1 | |
| SCHEMBL4258273 | 0.81 | IMPDH2 (0.80) | IMPDH2AAK1 | |
| SCHEMBL4253104 | 0.81 | IMPDH2 (0.80) | IMPDH2AAK1 | |
| SCHEMBL14518615 | 0.79 | IMPDH2 (0.74) | IMPDH2AAK1 | |
| SCHEMBL5531405 | 0.78 | AAK1 (0.75) | IMPDH2AAK1 | |
| SCHEMBL6495167 | 0.77 | IMPDH2 (0.79) | IMPDH2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | claimed |
| EP-1127054-A4 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2006-11-02 | — | — | EP | claimed |
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H | 2006-06-08 | — | — | US | claimed |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-05-27 | — | — | US | claimed |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H (US) | 2004-04-29 | — | — | US | claimed |
| EP-1127054-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000026197-A9 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2000-10-26 | — | — | WO | claimed |
| WO-2000026197-A1 | NOVEL INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | claimed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| US-7205324-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | GU HENRY H | 2006-06-08 | — | — | US | disclosed |
| US-7053111-B2 | Inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB CO. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| US-6624184-B1 | Identification of the inhibitors of IMPDH (inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH associated disorders, and | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122245-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885NPC1 1295/4885RAB9A 2318/4885 |
| US-20040082562-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885NPC1 1340/4885RAB9A 2298/4885 |
| US-20040102497-A1 | Novel inhibitors of IMPDH enzyme | IMPDH1, IMPDH2, IMPA1 | IMPDH2 2/4885NPC1 1340/4885RAB9A 2298/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885NPC1 1370/4885RAB9A 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.